|
10206
|
GEO-EM05
|
Marburg hemorrhagic fever
|
Hemorrhagic
|
Marburg virus
|
negative-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
GeoVax Labs Inc.
|
NA
|
USA
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.biospace.com/article/geovax-announces-100-percent-protection-data-from-marburg-virus-vaccine-study/
|
NA
|
|
10207
|
AVI-6003
|
Marburg hemorrhagic fever
|
Hemorrhagic
|
Marburg virus
|
negative-sense, single-stranded RNA
|
NA
|
Phase 1
|
Sarepta Therapeutics Inc.
|
2012
|
USA
|
18 - 55 years
|
NA
|
Intravenous
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT01353040
|
https://clinicaltrials.gov/ct2/show/NCT01353040?cond=Marburg+hemorrhagic+fever&draw=2&rank=1
|
NA
|
|
10208
|
cAd3 Marburg (VRC-MARADC087-00-VP)
|
Marburg hemorrhagic fever
|
Hemorrhagic
|
Marburg virus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 1
|
National Institute of Allergy and Infectious Diseases
|
2021
|
USA
|
18 - 50 years
|
Single dose
|
Intramuscular
|
NA
|
Marburg wild type glycoprotein
|
NA
|
US FDA
|
US Military HIV Research Program
|
NA
|
NA
|
NA
|
NCT03475056
|
https://clinicaltrials.gov/ct2/show/NCT03475056?cond=Marburg+hemorrhagic+fever&draw=2&rank=3
|
NA
|